“…[77][78][79] Furthermore, Cy5 has been successfully used in recently developed opioid fluorescent probes that have been successfully used both in vitro and in vivo. 47,48,59,[80][81][82] In previous studies [33][34][35][36] it had been shown that the implementation of a linker on the guanidinyl NH leads to molecules which can retain affinity, antagonistic activity and selectivity for the KOR. Inspired by these studies, and also by investigations highlighting the contribution of the linker's length and physicochemical properties in avoiding non-specific binding and preserving the pharmacological profile of the prototype ligand, 60,61,[83][84][85] we designed three sets of fluorescent probes: a) compounds 9a and 9b, which bear a 11-bond aliphatic linker (Scheme 1); b) compound 13, which bears a 17-bond linker with the incorporation of a diglycine moiety (Scheme 2); c) compounds 17a and 17b, which bears a 23-bond linker with the incorporation of a tetraglycine moiety (Scheme 2).…”